A prodrug form of EIDD-1931
Molnupiravir is a prodrug form of the antiviral ribonucleoside analog EIDD-1931 .1,2 Molnupiravir (500 mg/kg) reduces body weight loss, lung hemorrhage, and lung viral titers, as well as improves pulmonary function in mouse models of severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome coronavirus (MERS-CoV) infection when administered prophylactically at 2 hours pre-infection or therapeutically at 12 hours post-infection.1 It also reduces shed virus load and fever in ferret models of H1N1 or H3N2 influenza A virus infection when administered at a dose of 100 mg/kg twice per day.2
1.Sheahan, T.P., Sims, A.C., Zhou, S., et al.An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in miceSci. Transl. Med.12(541)eabb5883(2020) 2.Toots, M., Yoon, J.-J., Cox, R.M., et al.Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epitheliaSci. Transl. Med.11(515)eaax5866(2019)
动态评分
0.0